Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2019 Jan 31

PMID 30697576

Citations 34

Authors

Maria R Ciardi

Marco Iannetta

Maria A Zingaropoli

Romina Salpini

Marianna Aragri

Rosanna Annecca

Simona Pontecorvo

Marta Altieri

Gianluca Russo

Valentina Svicher

Claudio M Mastroianni

Vincenzo Vullo

Affiliations

Soon will be listed here.

Abstract

Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DNA and HBV surface antigen periodic assessment. Anti-HBV treatment with entecavir was started after HBV-DNA detection. Ocrelizumab can reactivate viral replication in patients with resolved HBV infection. HBV reactivation monitoring seems an effective and safe option for the management of these patients. More studies are needed to assess the optimal management of HBV reactivation in MS patients on ocrelizumab treatment.

Citing Articles

Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.

Carvajal R, Guananga-Alvarez D, Tur C, Esperalba J, Rodriguez-Barranco M, Rando-Segura A Neurology. 2025; 104(3):e210281.

PMID: 39819099 PMC: 11737845. DOI: 10.1212/WNL.0000000000210281.

Genetic variations and gene expression profiles of Rice Black-streaked dwarf virus (RBSDV) in different host plants and insect vectors: insights from RNA-Seq analysis.

Lagzian A, Ghorbani A, Tabein S, Riseh R BMC Genomics. 2024; 25(1):736.

PMID: 39080552 PMC: 11289972. DOI: 10.1186/s12864-024-10649-9.

Ocrelizumab-induced organizing pneumonia in multiple sclerosis: case report and literature review.

Usman S, Cheema M, Ghuman Z, Mustafa S, Iftikhar A Arch Clin Cases. 2024; 11(2):69-73.

PMID: 39015300 PMC: 11250650. DOI: 10.22551/2024.43.1102.10291.

Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.

Erdogan T, Cansu C, Kocer B, Akkaya S, Kokmen H Acta Neurol Belg. 2024; 124(4):1385-1391.

PMID: 38769274 DOI: 10.1007/s13760-024-02572-3.

Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies.

Ma H, Yan Q, Ma J, Li D, Yang J World J Gastroenterol. 2024; 30(10):1295-1312.

PMID: 38596493 PMC: 11000084. DOI: 10.3748/wjg.v30.i10.1295.

References

Sheldon J, Soriano V . Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother. 2008; 61(4):766-8. DOI: 10.1093/jac/dkn014. View

Emery P, Rigby W, Tak P, Dorner T, Olech E, Martin C . Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014; 9(2):e87379. PMC: 3911947. DOI: 10.1371/journal.pone.0087379. View

Salpini R, Colagrossi L, Bellocchi M, Surdo M, Becker C, Alteri C . Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology. 2014; 61(3):823-33. DOI: 10.1002/hep.27604. View

Reddy K, Beavers K, Hammond S, Lim J, Falck-Ytter Y . American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2014; 148(1):215-9. DOI: 10.1053/j.gastro.2014.10.039. View

De Nard F, Todoerti M, Grosso V, Monti S, Breda S, Rossi S . Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol. 2015; 7(3):344-61. PMC: 4381162. DOI: 10.4254/wjh.v7.i3.344. View

Varisco V, Vigano M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P . Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. J Rheumatol. 2016; 43(5):869-74. DOI: 10.3899/jrheum.151105. View

Hauser S, Bar-Or A, Comi G, Giovannoni G, Hartung H, Hemmer B . Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2016; 376(3):221-234. DOI: 10.1056/NEJMoa1601277. View

Montalban X, Hauser S, Kappos L, Arnold D, Bar-Or A, Comi G . Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2016; 376(3):209-220. DOI: 10.1056/NEJMoa1606468. View

Loomba R, Liang T . Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017; 152(6):1297-1309. PMC: 5501983. DOI: 10.1053/j.gastro.2017.02.009. View

10.

. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370-398. DOI: 10.1016/j.jhep.2017.03.021. View

11.

Gelfand J, Cree B, Hauser S . Ocrelizumab and Other CD20 B-Cell-Depleting Therapies in Multiple Sclerosis. Neurotherapeutics. 2017; 14(4):835-841. PMC: 5722762. DOI: 10.1007/s13311-017-0557-4. View

12.

Terrault N, Lok A, McMahon B, Chang K, Hwang J, Jonas M . Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67(4):1560-1599. PMC: 5975958. DOI: 10.1002/hep.29800. View

13.

Colagrossi L, Hermans L, Salpini R, Di Carlo D, Pas S, Alvarez M . Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. BMC Infect Dis. 2018; 18(1):251. PMC: 5984771. DOI: 10.1186/s12879-018-3161-2. View